Sree Chitra Tirunal Institute For Medical Sciences And Technology, Thiruvananthapuram

Most medical institutes in India treat patients; SCTIMST also invents the hardware used to treat them. The institute developed an indigenous artificial heart valve that is now manufactured and marketed by the TTK group, and it did so on the same Thiruvananthapuram campus where it runs a cardiac and neurological referral hospital. It is stranger still on paper: alone among India's medical institutes of national importance, it answers to the Department of Science and Technology rather than the health ministry. For an applicant that means no MBBS seat and no NEET-UG. Even so, its clinical DM and MCh seats turn on a national all-India rank from the AIIMS-run INI-SS exam, and only the biomedical-technology and public-health programmes are decided on a test the institute sets itself.

SCTIMST began in 1976 as the Sree Chitra Tirunal Medical Centre and was raised to an Institute of National Importance by an Act of Parliament in 1980, taking its present name then, per the institute's history record. What sets it apart from the AIIMS-tier institutes is its parent ministry: SCTIMST is run as an Institution of National Importance under the Department of Science and Technology, Government of India, which is why device research sits beside clinical medicine in its mandate rather than being an afterthought to it.

The institute is built as three wings that rarely share a roof anywhere else in the country. The Hospital Wing is a tertiary referral centre for cardiovascular, thoracic and neurological disease; the Biomedical Technology Wing at Poojappura designs and tests medical devices; and the Achutha Menon Centre for Health Science Studies works in public health, a division set up in 2000, per the same institute record. A student here is joining a body that treats the patient, engineers the implant, and studies the population the disease came from.

There is no first medical degree on the SCTIMST list. Its clinical intake is entirely doctoral and super-specialty: DM programmes in Cardiology, Neurology and Neuroanaesthesia, MCh programmes in Cardiovascular and Thoracic Surgery, Neurosurgery and Vascular Surgery, an MD in Transfusion Medicine, and Post Doctoral Certificate Courses, all listed on the official admissions page. Around that clinical core sit the routes the other two wings own: an M.Tech and MPhil in biomedical technology, a Master of Public Health and a Diploma in Public Health, PhD research, and technical diplomas in fields such as clinical perfusion, blood banking and medical imaging technology.

SCTIMST does not print a single consolidated fee on its admissions page, and the amount differs sharply between a super-specialty residency, a technology master's and a public-health diploma. The binding figure for any one course is the fee set out in that programme's prospectus, which an applicant reaches through the institute's own student application portal when the session opens. Read that prospectus for the exact tuition, caution deposit and application fee rather than a headline number quoted on a listings site, because these are notified per programme and per session.

Admission at SCTIMST runs on two separate tracks, and which one applies depends entirely on the programme. Its clinical super-specialty seats are not an in-house selection: the DM programmes in Cardiology, Neurology and Neuroanaesthesia and the MCh programmes in cardiac, neuro and vascular surgery are allotted on the all-India INI-SS rank, the super-specialty entrance AIIMS New Delhi conducts, which lists SCTIMST among its participating Institutes of National Importance. The MD in Transfusion Medicine is filled the same way, on the INI-CET rank, the combined postgraduate entrance the same institutes share. A clinical applicant here therefore competes on a national merit number against candidates across that whole network, not on a paper SCTIMST marks on its own.

The second track is the one the institute runs itself, and it sits outside clinical medicine altogether. The M.Tech and MPhil in biomedical technology, the Master of Public Health, the public-health and technical diplomas, and PhD research are selected on SCTIMST's own entrance test and interview, with candidates registering on its student portal. Eligibility is matched to the programme on either track: a DM seat needs a relevant MD, an MCh seat the relevant MS or an equivalent qualification, the MD in Transfusion Medicine an MBBS, and the Master of Public Health takes medical and dental graduates alongside AYUSH and allied-science degree holders. The rule that saves an applicant trouble is to read the exact programme first, because a super-specialty seat is won on a national rank while a technology or public-health seat is won on the institute's own list.

There is no single SCTIMST cutoff, and the reason is that its seats close on two different rank lists. For the clinical DM and MCh programmes the closing figure is an all-India INI-SS rank, and for the MD in Transfusion Medicine an INI-CET rank, both settled nationally through the AIIMS counselling rather than inside Thiruvananthapuram. For the M.Tech, MPH, diploma and PhD seats the closing mark is the institute's own programme-wise list instead. A Cardiology super-specialty seat and an MPH seat are therefore graded on entirely different scales, and because each branch takes only a handful of candidates a session, one unusually strong or thin year moves either far more than any eligibility rule would.

So the cutoff worth planning against depends on which track you are on. A clinical aspirant watches the INI-SS or INI-CET closing rank for their branch in the AIIMS counselling result; a technology or public-health aspirant watches the institute's own rank list for the exact programme, published on its admissions page after that test. Either way, treat any single "SCTIMST cutoff" quoted ahead of the results as guesswork, because the number is decided only once the relevant exam is marked.

SCTIMST is one of the few super-specialty medical institutes that reports real placement salaries in its ranking return, because its output is not only clinicians but biomedical technologists and public-health specialists who take salaried posts. In its NIRF 2025 data submission the institute recorded that of its 2023-24 three-year-programme leavers, 34 graduated in the stipulated time, 23 were placed at a median of Rs 28,80,000 a year, and 11 moved on to higher study. Its two-year-programme leavers that year numbered 62, of whom 56 were placed at a median of Rs 7,55,400 and 6 continued to higher study.

Those medians read the way a specialist pipeline should: the doctoral and super-specialty cohort commands a far higher figure than the shorter technical and public-health programmes, and a slice of every batch chooses another degree over a first job. The clearest single measure of clinical throughput is the super-specialty count, and the NIRF 2025 submission records 36 students graduating from its DM and MCh programmes in 2023-24. A prospective resident should read that as the institute's real function: it turns already-qualified doctors into cardiac and neuro super-specialists, not into campus-placement candidates.

The institute publishes sanctioned intake by programme group rather than as one combined figure, and there is no undergraduate row at all because it admits no MBBS batch. Its most recent NIRF 2025 submission records an approved intake of 70 seats across its two-year postgraduate programmes and 49 across its three-year programmes for 2023-24, the latter up from 38 the year before.

Within those totals the seats are split by course, category and the reserved-quota roster, and the exact per-programme break-up is re-notified each admission cycle. For a specific DM, MCh or MPH course, the seats that actually exist are the ones in that programme's own session notification; the group totals above only describe the institute's overall scale.

The Ministry of Education's National Institutional Ranking Framework places SCTIMST at rank 17 in the country's Medical table for 2025, on an overall score of 63.36, per the NIRF 2025 Medical ranking. It does not appear in the Overall or University tables, which is expected for an institute this specialised and this small; judged inside its own field it sits comfortably in the top 20.

For a small institute whose research is device-oriented rather than paper-heavy, the shape of the breakdown is predictable: its teaching and graduation marks carry the rank, its research score sits mid-table for a hospital of its bed count, and peer perception, where a narrow Kerala institute is judged against the country's largest general hospitals, is the one parameter that drags on it. The rank and each parameter score sit in the table below.

The clinical departments cluster tightly around the two organ systems the hospital is built for. On the cardiac side sit Cardiology, Cardiovascular and Thoracic Surgery, Cardiac Anaesthesia and the cardiac imaging and perfusion services; on the neurological side sit Neurology, Neurosurgery, Neuroanaesthesia and interventional neuroradiology. Transfusion Medicine runs as its own department and carries the institute's only MD. This is a deliberately shallow but deep map: SCTIMST does not spread across every specialty, it goes very far into two.

The department a prospective applicant should study, though, is often not a clinical one. The Biomedical Technology Wing houses laboratories in areas such as biomaterials, medical devices and tissue engineering, and it is where the institute's device work, the heart valve, the blood-bag system and the blood oxygenators among them, actually happens. The Achutha Menon Centre carries the public-health and biostatistics teaching. So the three wings are three different institutions to apply to, and the right page to read before applying is the target wing's, not the institute overview.

The hospital that anchors the campus is a compact tertiary facility rather than a sprawling one. In its NIRF 2025 submission SCTIMST reported 253 hospital beds with an average daily occupancy of 207 and an average outpatient attendance of 436 a day in the 2023 calendar year, the caseload a resident actually trains on. For a super-specialty institute the value is concentration: those beds are cardiac and neuro cases sent in from across Kerala and beyond, so the exposure per bed is unusually high.

Beyond the wards the campus is a research plant as much as a hospital. The Biomedical Technology Wing at Poojappura runs device-development and testing laboratories, and the institute's research base is heavy for its bed count: the same submission records 161 sponsored research projects running in 2023-24, up from 112 the year before, per the NIRF 2025 submission. A hospital that size carrying that many funded projects is the clearest sign that the device wing and the wards are one operation, not two.

SCTIMST does not set out its hostel rooms, eligibility or charges on its public admissions page, so a confirmed residential place should be settled with the academic section rather than assumed on the strength of a listings-site figure. Because the clinical residents here are already qualified doctors on stipend rather than school leavers, campus housing works differently from an undergraduate college hostel, and the room rules and any charges are handled programme by programme. Confirm the current accommodation position for your specific course directly with the institute before you join.

The 144 faculty members SCTIMST entered in its NIRF 2025 submission are split across three unlike jobs: clinicians in the hospital wing, device engineers and biomaterials scientists in the technology wing, and epidemiologists and biostatisticians in the public-health centre. Since none of them run an MBBS class, the whole strength goes into doctoral and super-specialty supervision, and in a field as narrow as cardiac or neuro medicine the consultant marking your DM viva is frequently the same one whose referral list you have spent the year working through.

The research load the faculty carry is unusually visible for a hospital. The same submission records 99 full-time PhD scholars alongside the clinical residents, so a meaningful part of the institute's population is doing device and biomedical research rather than ward work, per the NIRF 2025 submission. That mix, clinicians and doctoral engineers under one faculty, is what a resident is really buying into here, and it is the reason the teaching-and-resources score carries the institute in the ranking.

SCTIMST keeps no public roster of celebrated graduates, and in its case the more honest measure of its people is what they built rather than who they became. The institute is best known for what its biomedical laboratories produced, an indigenous heart valve now made and sold by the TTK group, a disposable blood-bag system and blood oxygenators among them, which reached Indian operating theatres through technology transfer, per the institute record.

For an applicant weighing the place, the more useful trajectory to note is where its clinical graduates go: DM and MCh holders from here move into cardiac and neuro consultant posts, faculty positions and referral-hospital services rather than into a placement-week table. What the institute can be judged on with certainty is that device record, which is documented in published technology transfers rather than in an alumni list it does not maintain.

The updates that matter to an applicant are the institute's own admission notices, and SCTIMST posts them to a live admissions page for each January and July session, where its own entrance-examination schedule, the programme-wise rank lists and the results appear as each stage opens. A clinical super-specialty aspirant tracks the AIIMS INI-SS and INI-CET calendar in parallel, since that exam is conducted centrally rather than by SCTIMST.

The institute's other news is of a kind few hospitals generate: announcements about its device work, technology transfers and biomedical research surface on its own site rather than through a press feed. A specific examination date or a published rank list is authoritative only on that admissions page, so an SCTIMST applicant reads it there first and treats a coaching-site calendar as second-hand until the two agree.

The fair peer set for SCTIMST is short, because almost nothing else in India pairs cardiac and neuro super-specialty training with an in-house medical-device laboratory. Set against the pure clinical super-specialty institutes, its distinguishing offer is the Biomedical Technology Wing: a candidate here can sit inside the group that designs implants and biomaterials, not only the one that uses them. That is the axis on which the choice actually turns for someone weighing SCTIMST, far more than a league-table position does.

For a device-minded applicant, then, the real question is which wing the target programme sits in, because a DM in Cardiology and an M.Tech in biomedical technology lead out of the same institute into very different careers. Judge the clinical branches on their seat counts and entrance papers and the technology and public-health streams on their own, and read each institution's published NIRF standing as one piece of evidence rather than the verdict.

SCTIMST is spread across Thiruvananthapuram in Kerala, with the Hospital Wing and academic blocks on the main campus and the Biomedical Technology Wing at Poojappura, per the institute site. Applications are made online through the institute's own student portal rather than by post, and the current phone numbers and departmental emails are listed on the official website.

At a glance

Quick facts